About Dewpoint Therapeutics
Dewpoint Therapeutics is a private company based in Boston, Massachusetts. It has reported $304,261,568 raised in three offerings on Form D since November 2020. Its chief executive is Ameet Nathwani, M.D..
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 9, 2025 | Sep 23, 2025amended Jul 13, 2026 | $77,164,102of $82.2M target | 23 | $3.3M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jan 26, 2022 | Feb 4, 2022 | $149,999,989fully sold | 18 | $8.3M | EquityRule 506(b) | Form D ↗ |
| Jul 7, 2020 | Nov 2, 2020 | $77,097,477fully sold | 25 | $3.0M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $304,261,568 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Dewpoint Therapeutics's Form D filed Jul 13, 2026.
Earlier filings also listed Lori Escobedo (executive officer, last listed Feb 2022), Juergen Eckhardt, M.D. (director, last listed Feb 2022), Joel Sendek (executive officer, last listed Feb 2022), Amir Nashat (director, last listed Feb 2022), Srinivas Akkaraju, M.D. (director, last listed Nov 2020), Oliver Brandicourt, M.D. (director, last listed Nov 2020), Jurgen Eckhardt, M.D. (director, last listed Nov 2020) and Giuseeppe Ciaramella, Ph.D. (director, last listed Nov 2020).